Loading
A phase 3 trial of CAR T cells in gastric & gastro-oesophageal junction cancer, run by Suzhou Immunofoco Biotechnology Co., Ltd, now recruiting.
A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients is a phase 3 interventional study registered as NCT07103668 by Suzhou Immunofoco Biotechnology Co., Ltd, with 150 participants planned, started 2025-08-06 and due to reach its primary completion in 2027-05-31. Interventions recorded: CAR T cells and Control.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Claudin 18.2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/